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Neuroblast and neuroblastoma expression profile<p>Tran criptome profiling of neu oblasts and neuroblastoma tumor cells provides strong support for a neuroblast origin of neuroblast-oma and highlights new candidate n ur blast ma genes</p>
Abstract
Background: Neuroblastoma tumor cells are assumed to originate from primitive neuroblasts giving rise to the
sympathetic nervous system. Because these precursor cells are not detectable in postnatal life, their transcription
profile has remained inaccessible for comparative data mining strategies in neuroblastoma. This study provides
the first genome-wide mRNA expression profile of these human fetal sympathetic neuroblasts. To this purpose,
small islets of normal neuroblasts were isolated by laser microdissection from human fetal adrenal glands.
Results: Expression of catecholamine metabolism genes, and neuronal and neuroendocrine markers in the
neuroblasts indicated that the proper cells were microdissected. The similarities in expression profile between
normal neuroblasts and malignant neuroblastomas provided strong evidence for the neuroblast origin hypothesis
of neuroblastoma. Next, supervised feature selection was used to identify the genes that are differentially
expressed in normal neuroblasts versus neuroblastoma tumors. This approach efficiently sifted out genes
previously reported in neuroblastoma expression profiling studies; most importantly, it also highlighted a series
of genes and pathways previously not mentioned in neuroblastoma biology but that were assumed to be involved
in neuroblastoma pathogenesis.
Conclusion: This unique dataset adds power to ongoing and future gene expression studies in neuroblastoma
and will facilitate the identification of molecular targets for novel therapies. In addition, this neuroblast
transcriptome resource could prove useful for the further study of human sympathoadrenal biogenesis.
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Neuroblastoma is the most common and deadly extracranial
solid childhood tumor, exhibiting remarkable variation in
clinical presentation ranging from localized to highly meta-
static disease. Despite multimodal therapies, survival rates
for aggressive neuroblastomas are still disappointingly low.
One possible approach to development of more efficient and
less toxic therapies is to gain insight into the signaling path-
ways that are deregulated in neuroblastoma and to use this
information in the design of molecular therapies. However, at
present only two genes, namely MYCN and PHOX2B, have
been directly linked to neuroblastoma development, although
their exact role in oncogenesis is still unclear [1,2].
It is hoped that genome-wide gene expression studies will
provide insights into the genes and molecular pathways that
govern neuroblastoma pathogenesis. Thus far, no clear or
consistent candidate genes or pathways have emerged from
these analyses [3-5] (see Additional data file 3 for more refer-
ences). Both for currently available expression data and forth-
coming datasets, we anticipate that transcriptome
information on the cells of origin of neuroblastoma (sympa-
thetic nervous system progenitors) will be of crucial impor-
tance and could provide significant power on data mining
strategies.
The sympathetic nervous system is composed of sympathetic
chain and truncus ganglia, paraganglia, and the adrenal
gland. Ganglion cells (neuroblasts during development) are
the major cell type of chain and truncus ganglia, and extra-
adrenal chromaffin cells form the paraganglia, whereas the
adrenal gland is composed of adrenal chromaffin cells and, at
least during development, sympathetic neuroblasts. The fate
of the neuroblasts in the developing human adrenal gland is
not clear; some or all may involute or mature as solitary intra-
adrenal neurons [6]. Evidence for the cellular origin of neu-
roblastoma is based on their occurrence in the adrenal gland
or along the spinal cord in association with sympathetic gan-
glia, and on their neuroblastic phenotype that indicates that
the tumor cells are derived from immature sympathetic nerv-
ous system cells of the ganglionic lineage [7]. Indeed, cells of
adrenal neuroblastomas have neuroblastic morphology and
do not express the adrenal chromaffin marker PNMT, but
they share phenotypic characteristics with the immature
sympathetic neuroblasts present as nests of cells in the devel-
oping adrenal gland. However, a small subset of neuroblasto-
mas also contains cells with extra-adrenal chromaffin
characteristics.
In the present study we isolated and performed expression
profiling of the human adrenal neuroblasts as they form
monocellular structures during early fetal stages, which can
be easily microdissected. In parallel, favorable and unfavora-
ble neuroblastoma tumors were profiled on the same plat-
form. Finally, our dataset was integrated in a meta-analytical
data mining approach.
Results
Characterization, isolation, and gene expression 
profiling of fetal adrenal neuroblasts
Prescreening of hematoxylin-eosin cryosections from 11 fetal
adrenal glands demonstrated that large neuroblast clusters of
more than 100 cells were predominantly found in adrenal
glands at 19 and 20 weeks' gestational age (Figure 1a). To ver-
ify that these cell clusters indeed represent neuroblasts and to
estimate the degree of intermingled chromaffin cells, cryosec-
tions were stained for the neuronal and chromaffin marker
TH (tyrosine hydroxylase), the chromaffin marker CHGA
(chromogranin A; which also has low expression in neurob-
lasts), and the neuronal markers BCL2 (B-cell CLL/lym-
phoma 2) and HNK1 (carbohydrate epitope) [8]. As shown in
Figure 1, the clusters of neuroblastic cells stained positive for
all markers and, in particular, these cells were positive for
BCL2 and HNK1. The majority of chromaffin cells, identified
by their strong CHGA and TH expression, were found to be
scattered throughout the adrenal cortex (these cells coalesce
and form large islands of chromaffin cells later during devel-
opment), whereas a few cells were located in or adjacent to
the neuroblast clusters.
Neuroblast clusters and adjacent cortical cells (used as con-
trols) were isolated using laser capture microdissection from
stained cryosections from three different fetal adrenal glands
(glands 1, 2 and 3, which were of gestational ages 20, 19 and
19 weeks, respectively) (Figure 2) and immediately lysed in
RNA extraction buffer. In order to obtain a sufficient amount
of good quality neuroblast RNA for oligonucleotide chip anal-
yses, we applied a previously validated protocol for tissue sec-
tioning, staining, and microdissection [9] (Additional data
file 1(a)). By pooling different isolates of the same adrenal
gland, between 2.5 and 15 ng total RNA could be obtained for
each of the three neuroblast samples (Additional data file
1(b)). After two-round amplification and labeling of three
neuroblast, three cortex, and 18 neuroblastoma RNA sam-
ples, hybridization was performed on HG-U133A Affymetrix
oligonucleotide chips. Real-time polymerase chain reaction
analysis of selected genes showed that there was no RNA
amplification bias in the chip data (Additional data file 1(c)).
Validation of the expression profile of fetal adrenal 
neuroblasts and cortex cells
The expression profiles of the neuroblast and cortex samples
were compared using the rank product nonparametric
method, which is particularly suited for extracting signifi-
cantly differentially expressed genes in a limited number of
samples [10]. Two lists of 156 and 86 unique genes were
established with significantly higher expression in neuroblast
and adrenal cortex cells, respectively (multiple testing cor-
rected P < 0.01; Additional data file 2). Gene Ontology (GO)
analysis identified those classes of genes that are significantly
over-represented in the cell specific gene lists (P < 0.01; Table
1). As expected, the neuroblast gene list is enriched for genes
that are involved in catecholamine metabolism, neurogenesisGenome Biology 2006, 7:R84
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nIdentification of sympathetic neuroblasts and chromaffin cells in human fetal adrenal glands by immunohistochemical analysisFigure 1
Identification of sympathetic neuroblasts and chromaffin cells in human fetal adrenal glands by immunohistochemical analysis. Sections of a human fetal (19 
weeks) adrenal gland, adjacent to those used for laser capture retrieval of cells for mRNA extraction and gene expression profiling, were stained with (a) 
hematoxylin and eosin or antibodies directed against (b,f) TH, (c,g) CHGA, (d,h) BCL2, and (e,i) HNK1. Whereas the immunoreactivities of BCL2 and 
HNK1 are specific for neuroblasts, TH and CHGA expression is pronounced in chromaffin cells and weak in neuroblasts [8]. Stars indicate chromaffin cells 
(TH+, CHGA+, BCL2-, and HNK1-), either solitary or intermingled with neuroblasts. Panels a-e show a cluster of adrenal neuroblasts and panels f-i show 
cortical area within scattered chromaffin cells adjacent to the neuroblast cluster. Inserts in panels b-e (bars: 10 µm) correspond to the boxed areas in 
these panels (bars in panels a-i: 100 µm). BCL2, B-cell CLL/lymphoma 2; CHGA, chromogranin A; H&E, hematoxylin and eosin; HNK1, carbohydrate 
epitope; TH, tyrosine hydroxylase.
Laser capture microdissection of neuroblast clustersFigure 2
Laser capture microdissection of neuroblast clusters. (a) Large cluster of neuroblasts in fetal adrenal glands at 19 weeks' gestational age (mounted 
hematoxylin and eosin stained cryosections), (b,c) unmounted hematoxylin and eosin stained fetal adrenal cryosections with a neuroblast cluster before 
and after microdissection (sample 2), and (d) the microdissected neuroblast cluster.
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R84.4 Genome Biology 2006,     Volume 7, Issue 9, Article R84       De Preter et al. http://genomebiology.com/2006/7/9/R84and other neural processes, whereas cortex cells specifically
express genes involved in steroid and cholesterol metabolism.
To further test the validity of the neuroblast gene expression
profile, we evaluated the expression of known neuronal and
chromaffin markers that were previously studied in human
fetal sections [8]. High expression (among the 10% most
Table 1
GO analysis: neuroblast versus cortex samples
GO P value n GO description
More highly expressed in neuroblast compared to cortex
GO:0007399 5.94E-09 20 Neurogenesis
GO:0019226 1.12E-06 13 Transmission of nerve impulse
GO:0007268 5.39E-06 12 Synaptic transmission
GO:0001505 9.29E-05 5 Regulation of neurotransmitter levels
GO:0007267 2.76E-04 16 Cell-cell signaling
GO:0050877 3.17E-04 16 Neurophysiological process
GO:0046879 3.47E-04 3 Hormone secretion
GO:0006584 3.47E-04 3 Catecholamine metabolism
GO:0018958 4.72E-04 3 Phenol metabolism
GO:0048513 6.67E-04 22 Organ development
GO:0006836 6.96E-04 4 Neurotransmitter transport
GO:0009887 7.32E-04 21 Organogenesis
GO:0007154 1.21E-03 46 Cell communication
GO:0045055 1.25E-03 3 Regulated secretory pathway
GO:0007269 1.25E-03 3 Neurotransmitter secretion
GO:0046903 1.52E-03 8 Secretion
GO:0030072 2.09E-03 2 Peptide hormone secretion
GO:0030073 2.09E-03 2 Insulin secretion
GO:0016079 2.09E-03 2 Synaptic vesicle exocytosis
GO:0042423 2.09E-03 2 Catecholamine biosynthesis
GO:0006887 2.24E-03 4 Exocytosis
GO:0009653 2.77E-03 23 Morphogenesis
GO:0007218 3.25E-03 4 Neuropeptide signaling pathway
GO:0007275 3.26E-03 29 Development
GO:0046883 5.70E-03 2 Regulation of hormone secretion
GO:0030182 7.26E-03 2 Neuron differentiation
GO:0048489 8.98E-03 2 Synaptic vesicle transport
More highly expressed in cortex compared to neuroblast
GO:0016126 4.18E-07 5 Sterol biosynthesis
GO:0006694 9.28E-07 6 Steroid biosynthesis
GO:0008202 4.32E-06 7 Steroid metabolism
GO:0016125 2.93E-05 5 Sterol metabolism
GO:0044255 6.74E-05 9 Cellular lipid metabolism
GO:0006629 8.75E-05 10 Lipid metabolism
GO:0008610 1.39E-04 6 Lipid biosynthesis
GO:0006695 2.97E-04 3 Cholesterol biosynthesis
GO:0006066 1.17E-03 6 Alcohol metabolism
GO:0008203 4.69E-03 3 Cholesterol metabolism
GO:0044242 4.97E-03 2 Cellular lipid catabolism
GO:0006118 7.90E-03 5 Electron transport
Shown are over-represented GO classes (biological process) (with P < 0.01 and at least two genes) in the list of genes that are more highly 
expressed in neuroblast than in cortex samples, and vice versa. GO, Gene Ontology.Genome Biology 2006, 7:R84
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nabundant genes) of neuronal markers (BCL2, GAP43, and
NPY) together with chromaffin (and to a lesser extent neuro-
nal) markers (CHGA, CHGB, DBH, DDC and TH) and an
adrenal chromaffin marker (PNMT) in the microdissected
cell clusters is in keeping with our observation that the neu-
roblast isolates are pure, with only rare intermingled chroma-
ffin cells (Figure 1).
Gene set enrichment analysis [11] based on expression of the
156 neuroblast-specific genes in 79 human tissues [12] was
performed in order to explore whether the microdissected
neuroblasts indeed have neural characteristics. The neurob-
lasts exhibit a significant overlap in expression with various
nervous system tissues (P < 0.05; fetal brain, prefrontal cor-
tex, brain amygdale, whole brain, occipital lobe, and hypoth-
alamus), further demonstrating that the proper cells were
microdissected.
Similarity between the expression profiles of 
neuroblast and neuroblastoma further supports the 
'cell of origin' concept
Although multiple lines of evidence indicate that neuroblast-
oma originates from immature sympathetic neuroblasts, the
mRNA expression repertoire of these neuroblasts and neu-
roblastomas have not yet been compared. Before our analysis,
we assumed that, in addition to differences resulting from
oncogenic transformation, both cell populations would
exhibit many cell type specific similarities.
Three data mining strategies were employed to investigate
this hypothesis. First, an unbiased multidimensional scaling
of all genes on the chip showed that the neuroblasts cluster
close to the neuroblastoma tumors and that both groups clus-
ter far away from the fetal adrenal cortex cells (Figure 3a).
Second, we extended our dataset with publicly available
expression profiles (measured on the same platform) from 79
normal tissues [12]and three neural stem cell cultures [13].
Based on the genes that are differentially expressed between
the neuroblasts and cortex samples (156 and 86 genes,
respectively), multidimensional scaling showed again that the
neuroblastoma tumors cluster close to the neuroblasts and
further away from the other normal tissues. Interestingly, the
neural stem cells also cluster close to the neuroblastomas and
neuroblasts (Figure 3b). These findings further support the
notion that adrenal neuroblasts are indeed of neuronal origin
with possible neuronal stem cell features, and the observed
considerable similarities to neuroblastomas in terms of
expression give further strength to the 'cell of origin' hypoth-
esis for neuroblastoma development.
Third, we looked for similarities in mRNA expression
between neuroblast and neuroblastoma by cataloging their
expression repertoire. We defined a reasonable cut-off to
determine whether a gene is expressed or not in a given sam-
ple (the mean percentage of present calls for the various
chips; Additional data file 1(d)). As such, the 36% most highly
expressed probe IDs in the cortex, neuroblast and neuroblas-
toma cells, were selected and compared in a Venn diagram.
This analysis clearly shows that neuroblasts have more
expressed genes in common with neuroblastoma than with
the cortex cells (432 versus 292; Figure 4a). GO analysis on
the common 432 genes revealed an expected over-represen-
tation of neurogenesis genes (P < 0.01; data not shown). Next,
we zoomed in on neurogenesis and transcription factor ontol-
ogy classes by performing a similar Venn diagram for these
gene sets, assuming their putative importance in neuroblast-
oma development. Interestingly, the similarities between
neuroblast and neuroblastoma are even more pronounced for
these two GO classes (Figure 4b, c).
Identifying genes and pathways putatively implicated in 
neuroblastoma pathogenesis through differential 
expression analysis of normal neuroblasts and 
neuroblastomas
In the final and most challenging part of our data mining
approach, we aimed to identify genes that are under-
expressed or over-expressed in neuroblastomas compared
with neuroblasts, because these genes and the pathways that
they govern might be involved in neuroblastoma develop-
ment or represent markers for the stage of developmental
arrest of neuroblastomas. Rank product analysis (multiple
testing corrected P < 0.01) yielded a list of 71 genes that were
more highly expressed in neuroblasts and 565 genes that were
more highly expressed in neuroblastomas (Additional data
file 2).
A first crucial step in our data mining strategy to identify
genes that are putatively involved in neuroblastoma was a
meta-analysis of our generated gene lists in published neu-
roblastoma microarray data. We used the Neuroblastoma
Gene Server (NBGS) which was developed in-house (see
Additional data file 3 for detailed information) to compare the
neuroblast-specific and neuroblastoma-specific gene lists
with genes that have been reported as differentially expressed
in 25 previous gene expression profiling studies conducted in
neuroblastoma (Additional data file 3). We found that as
many as 17 of the 71 genes (24%) that are over-expressed in
neuroblasts relative to neuroblastomas were reported in the
NBGS, mainly annotated as genes that are more highly
expressed in maturing, differentiating, or localized
neuroblastomas. Likewise, 102 out of the 565 genes (18%)
that were over-expressed in neuroblastoma were previously
identified in other gene expression studies on neuroblastoma.
The high overlap of our gene lists with published gene lists
demonstrates the validity of our lists, which were subse-
quently further explored in chromosomal mapping, GO, and
pathway analysis.
Positional expression mapping of candidate oncogenes 
and tumor suppressor genes
Chromosome 17q gain is the most frequent genetic aberration
in neuroblastoma and is assumed to play a crucial role in itsGenome Biology 2006, 7:R84
R84.6 Genome Biology 2006,     Volume 7, Issue 9, Article R84       De Preter et al. http://genomebiology.com/2006/7/9/R84Multidimensional scaling of neuroblast, cortex, and neuroblastoma samplesFigure 3
Multidimensional scaling of neuroblast, cortex, and neuroblastoma samples. (a) Multidimensional scaling of neuroblast, cortex, and neuroblastoma samples 
using all genes (Spearman correlation) and (b) multidimensional scaling of neuroblast, cortex, neuroblastoma, 79 normal tissue samples and other cancer 
samples (in duplo), and three neural stem cell cultures using the genes that are differentially expressed between fetal adrenal neuroblast and fetal adrenal 
cortex shows that the neuroblasts cluster very close to the neuroblastomas.
Venn diagram analysis of the genes with detectable expression in neuroblastoma, neuroblast, and cortex samplesFigure 4
Venn diagram analysis of the genes with detectable expression in neuroblastoma, neuroblast, and cortex samples. (a) All genes, (b) transcription factors 
(GO:0003700), and (c) neurogenesis genes (GO:0007399). The number of genes that are in common between neuroblast and neuroblastoma is higher 
than the number of genes that are in common between the neuroblasts and cortex samples (especially for the gene classes transcription and 
neurogenesis), indicating that neuroblastomas resemble neuroblasts. GO, Gene Ontology.
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npathogenesis through a dosage effect of one or more genes.
This critical region still comprises 25 megabases (Mb) [14],
precluding straightforward candidate gene identification.
Here we apply an alternative, intuitive strategy to pinpoint
putative critical dosage sensitive loci. Using positional gene
enrichment analysis (De Preter and coworkers, unpublished
data) [15], we sought chromosomal loci that are significantly
over-represented in the list of genes that are over-expressed
in neuroblastoma relative to their normal cells of origin (Fig-
ure 5). We found two peaks on chromosome 17q, with high
significance for a locus on 17q21.32-q22 that coincides with
the consistently gained segment just distal from the most dis-
tal breakpoint in a series of high-resolution copy number pro-
files (Vandesompele and coworkers, unpublished data).
Apart from over-expressed genes, we also sought positional
tumor suppressor genes by mapping under-expressed genes
(relative to normal neuroblasts). The following positional
candidates could be identified, located within or very close to
the known shortest regions of overlap in neuroblastoma:
CASP9 on 1p36; CACNA2D3, TDGF1 and NKTR on 3p21-p22
(SRO (shortest region of overlap) from [16]); IGSF4, APOA1,
MLL and RDX on 11q23 [17-19]; and MEG3 and DLK1 on
14q32 [20].
GO analysis
To examine gene expression differences between neuroblasts
and neuroblastomas from a different perspective, we mapped
the neuroblast-specific and neuroblastoma-specific gene lists
to the biologic process GO classification (Table 2). This
revealed that the neuroblasts express significantly (P < 0.01)
more genes that are involved in steroid and catecholamine
metabolism compared with neuroblastomas. Neuroblasto-
mas are characterized by an over-representation of genes that
are involved in immune response, cell growth, and cell cycle.
The immune response gene signature may be due to infiltrat-
ing immune cells, whereas the over-representation of cell
growth and cell cycle genes in neuroblastomas is in perfect
concordance with the hyperproliferative character of tumors.
Positional gene enrichment analysis of genes on chromosome 17Figure 5
Positional gene enrichment analysis of genes on chromosome 17. Positional gene enrichment analysis for the genes that are more highly expressed in 
neuroblastoma compared to normal neuroblasts identified two regions on 17q with significant over-representation (-10log P values; indicated in grey; the 
genes in these regions are printed in the boxes). The horizontal red line indicates the multiple testing corrected P value of 0.01, above which the positional 
gene enrichment value denotes significant over-representation. Vertical lines show the position of the genes on chromosome 17 from the gene list under 
investigation. The boxplot shows the gene density along the chromosome.
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GO analysis: normal neuroblasts compared to neuroblastomas
GO P value n GO description
More highly expressed in neuroblast compared to neuroblastoma
GO:0008202 1.33E-18 17 Steroid metabolism
GO:0006694 3.22E-15 12 Steroid biosynthesis
GO:0044255 2.13E-12 18 Cellular lipid metabolism
GO:0008610 8.54E-12 13 Lipid biosynthesis
GO:0016125 1.29E-11 10 Sterol metabolism
GO:0006629 1.50E-10 18 Lipid metabolism
GO:0008203 5.85E-09 8 Cholesterol metabolism
GO:0008207 1.37E-08 5 C21-steroid hormone metabolism
GO:0006700 1.37E-08 5 C21-steroid hormone biosynthesis
GO:0006066 1.55E-08 12 Alcohol metabolism
GO:0042446 9.26E-07 5 Hormone biosynthesis
GO:0016126 1.16E-06 5 Sterol biosynthesis
GO:0042445 9.57E-06 5 Hormone metabolism
GO:0006118 1.76E-05 9 Electron transport
GO:0006869 1.84E-05 5 Lipid transport
GO:0009058 4.62E-05 16 Biosynthesis
GO:0006695 5.39E-04 3 Cholesterol biosynthesis
GO:0042423 6.50E-04 2 Catecholamine biosynthesis
GO:0006810 2.29E-03 20 Transport
GO:0006091 2.32E-03 9 Generation of precursor metabolites and energy
GO:0006584 2.85E-03 2 Catecholamine metabolism
GO:0051234 2.88E-03 20 Establishment of localization
GO:0051179 3.04E-03 20 Localization
GO:0018958 3.46E-03 2 Phenol metabolism
GO:0042401 5.64E-03 2 Biogenic amine biosynthesis
GO:0042398 8.30E-03 2 Amino acid derivative biosynthesis
More highly expressed in neuroblastoma compared to neuroblast
GO:0019882 4.54E-14 16 Antigen presentation
GO:0030333 2.51E-12 14 Antigen processing
GO:0019884 1.21E-08 8 Antigen presentation, exogenous antigen
GO:0019886 3.45E-08 8 Antigen processing, exogenous antigen via MHC class II
GO:0019883 4.23E-07 7 Antigen presentation, endogenous antigen
GO:0006260 2.07E-06 20 DNA replication
GO:0006955 2.45E-06 58 Immune response
GO:0006952 1.02E-05 60 Defense response
GO:0019885 1.03E-05 6 Antigen processing, endogenous antigen via MHC class I
GO:0009607 1.05E-05 66 Response to biotic stimulus
GO:0006270 9.25E-05 6 DNA replication initiation
GO:0006259 4.34E-04 35 DNA metabolism
GO:0009596 5.51E-04 4 Detection of pest, pathogen or parasite
GO:0006261 7.72E-04 10 DNA-dependent DNA replication
GO:0050896 1.03E-03 92 Response to stimulus
GO:0006913 1.42E-03 12 Nucleocytoplasmic transport
GO:0007051 1.84E-03 5 Spindle organization and biogenesis
GO:0016070 2.01E-03 25 RNA metabolism
GO:0007052 2.27E-03 4 Mitotic spindle organization and biogenesis
GO:0009595 2.27E-03 4 Detection of biotic stimulus
GO:0007017 2.67E-03 11 Microtubule-based process
GO:0006658 3.08E-03 2 Phosphatidylserine metabolism
GO:0009613 3.39E-03 34 Response to pest, pathogen or parasiteGenome Biology 2006, 7:R84
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nWe then specifically looked at genes belonging to GO terms
neurogenesis, transcription factor activity, and apoptosis;
these three processes can be assumed to play an important
role in neuroblastoma pathogenesis (Table 3). This analysis
identified the following interesting genes from the neurob-
last-specific and neuroblastoma-specific gene lists: transcrip-
tion factors involved in neurogenesis TFAP2B (6p12.3; more
highly expressed in neuroblasts); ASCL1 (12q23.2), SIX3
(2p21) and STAT3 (17q21.2; more highly expressed in neu-
roblastoma); and APOE (19q13.31) and INHBA (7p14.1; more
highly expressed in neuroblastoma), which are involved in
both apoptosis and neurogenesis.
Differential expression analysis of favorable and 
unfavorable neuroblastomas
Thus far, most published microarray studies on neuroblasto-
mas mainly compared favorable with unfavorable neuroblas-
tomas in order to identify prognostic markers or pathways
that are involved in these clearly different neuroblastoma
tumor types. In order to add value to such an analysis, we con-
trasted similar differentially expressed gene lists with the
normal neuroblast expression profile (Additional data file 2).
In a first step, we compared the differentially expressed genes
between these two tumor types with published prognostic
gene lists. We found that 25 of the 194 genes on our list were
previously reported, including the well established markers
MYCN, NTRK1, and CD44 (see NBGS analysis in Additional
data file 3). This overlap demonstrates the validity of the
selected neuroblastoma panel and their expression profile.
Subsequently, we sought the corresponding gene expression
levels of the differentially expressed genes in the normal
counterpart cells, aiming to select neuroblastoma candidate
genes. Of the 95 genes that are more highly expressed in favo-
rable tumors (versus unfavorable ones), 37 also have signifi-
cant differential expression (either higher or lower)
compared with neuroblasts, whereas 41 out of the 101 genes
that are more highly expressed in unfavorable tumors exhibit
differential expression compared with the neuroblasts (Table
4).
From this analysis, a few putative positional tumor suppres-
sor candidates emerge: CDC42 on 1p36, CACNA2D3 on 3p21,
and DLK1 on 14q. The latter two genes are of particular inter-
GO:0006928 3.94E-03 18 Cell motility
GO:0040011 3.94E-03 18 Locomotion
GO:0043207 4.72E-03 34 Response to external biotic stimulus
GO:0007626 5.10E-03 18 Locomotory behavior
GO:0016043 5.31E-03 46 Cell organization and biogenesis
GO:0016049 6.09E-03 12 Cell growth
GO:0008361 6.09E-03 12 Regulation of cell size
GO:0042254 6.39E-03 6 Ribosome biogenesis and assembly
GO:0051169 8.15E-03 10 Nuclear transport
GO:0016071 8.34E-03 16 Mrna metabolism
GO:0043241 8.91E-03 2 Protein complex disassembly
GO:0031498 8.91E-03 2 Chromatin disassembly
GO:0006337 8.91E-03 2 Nucleosome disassembly
GO:0006104 8.91E-03 2 Succinyl-coa metabolism
GO:0007610 9.44E-03 21 Behavior
GO:0007049 9.50E-03 39 Cell cycle
Shown are over-represented GO classes (biological process) (with P < 0.01 and at least two genes) in the list of genes that are more highly expressed 
in normal neuroblasts than in neuroblastomas, and vice versa. GO, Gene Ontology.
Table 2 (Continued)
GO analysis: normal neuroblasts compared to neuroblastomas
Venn diagram analysis of genes with detectable expression in neuroblast, n urobl sto a, and neural stem cell linesFigure 6
Venn diagram analysis of genes with detectable expression in neuroblast, 
neuroblastoma, and neural stem cell lines. This analysis shows that 
neuroblasts have many genes in common with neuroblastoma, but it also 
demonstrates that neural stem cell lines have more genes in common with 
the neuroblastomas than with the normal neuroblasts.
156 946 357
844
361 112
4581
Neuroblastoma Neuroblast
Neuralstem cellGenome Biology 2006, 7:R84
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rable neuroblastomas, and their expression is significantly
lower in unfavorable neuroblastomas. Among the genes that
are more highly expressed in unfavorable neuroblastomas
than in favorable ones and neuroblasts, the proven oncogenic
transcription factor MYCN emerges (and putative
downstream genes KIFAP3, OPHN1, RGS7, ODC1, TOP2A,
TWIST1 and TYMS, according to NBGS), as do several other
genes that have been identified or studied within the context
of neuroblastomas such as ALK and PRAME, and positional
candidates on 17q including BIRC5, RNU2 and TOP2A.
Expression of neurogenesis markers in neuroblasts and 
developmental origin of neuroblastoma
Although this was not the primary aim of the present work,
the neuroblast expression profile provides a unique resource
for the investigation of gene expression in human sympatho-
adrenal progenitors. In a first attempt, we made an inventory
of the genes that belong to the neurogenesis GO class, or that
have been described to play a role in neural crest formation
and migration, or that have proneural activity (Additional
data file 4). This analysis showed that human fetal neurob-
lasts of 19 weeks' gestational age expressed 174 of the 359
genes in the neurogenesis GO class, and 26 of 89 proneural
genes and genes involved in neural crest formation/migra-
tion.
To obtain possible clues on the developmental origin of neu-
roblastoma we compared the expression profiles of the neu-
roblastoma tumors with those of normal neuroblasts and
neural stem cell cultures. Intersectional Venn diagram
analysis of expressed genes shows that neuroblastomas have
many genes in common with neuroblasts, as already shown
above (Figure 6). Interestingly, when compared with
neuroblasts, the neuroblastomas have more genes in com-
mon with the self-renewing neural stem cells (535 versus
145), among others the neurogenesis genes ASCL1, GSS,
STAT3, UTP11L, ENAH, APBB2, CDK5RAP2, and LARGE.
Table 3
Differentially expressed transcription factors, neurogenesis, and apoptosis genes
Transcription factor (GO:0003700) Neurogenesis (GO:0007399) Apoptosis (GO:0006915)
Gene name Location Gene name Location Gene name Location
Neuroblast > neuroblastoma MLL 11q APOE 19q APOE 19q
NR0B1 Xp GREM1 15q PLAGL1 6q
RORA 15q TFAP2B 6p SCARB1 12q
TFAP2B 6p TDGF1 3p
Neuroblast < neuroblastoma ASCL1* 12q ALK 2p BCL2 18q
ATF3 1q APBB2 4p BCLAF1 6q
CNOT7 8p ASCL1 12q BIRC5 17q
CUTL2 12q CDK5R1 17q CCL2 17q
ETV6 12p FEZ1 11q CD2 1p
FOXC1 6p GPI 19q CD74 5q
HCLS1 3q INHBA 7p CIAPIN1 16q
IRF8 16q LARGE 22q CYCS 7p
KLF10 8q MBNL1 3q HTRA2 2p
MLX 17q NEFH 22q IER3 6p
NFE2L1 17q NTRK3 15q IGFBP3 7p
NFIB 9p OLFM1 9q INHBA 7p
NME2 17q PPT1 1p ITGB2 21q
RUNX1 21q SERPINF1 17p ITGB3BP 1p
SIX3 2p SIX3 2p LGALS1 22q
STAT1 2q SLIT1 10q LY86 6p
STAT3 17q SOX11 2p OPA1 3q
TAF10 11p STAT3 17q PRKCA 17q
TAF7 5q TRAPPC4 11q RNF130 5q
TFDP1 13q STAT1 2q
TRIM22 11p SULF1 8q
TSC22D1 13q TNFRSF21 6p
ZNF91 19p TUBB 6p
Shown are differentially expressed genes in neuroblastoma versus neuroblasts that belong to GO terms transcription factor, neurogenesis, and/or 
apoptosis, with an indication of the chromosomal localization. GO, Gene Ontology.Genome Biology 2006, 7:R84
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Genes that are differentially expressed in favorable vs. unfavorable neuroblastoma
Favorable NB > unfavorable NB NBGS Favorable NB < unfavorable NB NBGS
neuroblast < favorable NB neuroblast < favorable NB, neuroblast < unfavorable NB
AKAP7 6q - FABP6 5q -
ARL7 2q - NEFL 8p -
ASPN 9q - NPY 7p -
BCL2 18q 1 neuroblast < unfavorable NB
C2orf23 2p - ALK 2p -
CALB1 8q - ASCL1 12q 1
CAMK2B 7p 2 BIRC5 17q 3
CD24 6q - C22orf18 22q -
CDC42 1p 1 C3 19p -
DDAH1 1p - CALCB 11p -
DNAPTP6 2q - CCNB1 5q 1
EPB41L3 18p 1 CD74 5q -
FAM70A Xq - CRH 8q -
KIFAP3 1q 1 CSPG3 19p -
OPHN1 Xq - DNCI1 7q -
PDLIM5 4q - DTL 1 1
PPAN 19p - F12 5q -
PRKCB1 16p 1 GFRA2 8p -
RGS7 1q 2 IGHG3 14q -
RNF11 1p - IGHM 14q -
ST6GALNAC5 1p - IGKC 2p 1
SV2C 5q - IGLC2 22q -
neuroblast > favorable NB, neuroblast > unfavorable NB LMO3 12p 1
CACNA2D3 3p - MGC27165 14q -
DLK1 14q 2 MLF1IP 4q 1
HBG1 11p - MMP9 20q 1
HBG2 11p - MYCN 2p 9
neuroblast > unfavorable NB NEFH
ALDH3A2 17p 1 ODC1 2p 3
DLC1 8p - OGDHL 10q -
EYA1 8q - P2RX5 17p -
GCH1 14q 1 PRAME 22q 1
HBA2 16p - RPS4Y1 Yp 1
KIAA0960 7p 1 SERPINF1 17p -
PTPRD 9p - TNFRSF10B 8p 2
PTPRK 6q - TOP2A 17q 1
SLC18A1 8p - TWIST1 7p 1
TFAP2B 6p - TYMS 18p -
TLN2 15q 1 XAGE1 Xp -
neuroblast > favorable NB, neuroblast < unfavorable NB
IGLJ3 22q 1Genome Biology 2006, 7:R84
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Comparison of the mRNA expression repertoire of cancer
with that of their normal counterpart cells is a commonly
applied strategy to elucidate the development and pathophys-
iology of the cancer type under study. For pediatric
neuroblastoma, fetal adrenal sympathetic neuroblasts are
assumed to be the cells of origin, but these cells are virtually
absent after birth and thus not readily accessible for analysis
[8]. In this study we were able, for the first time, to determine
the expression profile of microdissected islets of fetal sympa-
thetic neuroblasts, providing an important landmark for
comparative expression analysis. In parallel, adjacent cortex
cells and carefully selected representative neuroblastoma
tumors were profiled for data mining purposes. Our main
goals were to provide support for the cell of origin hypothesis
of neuroblastoma, and to obtain preliminary insights into the
disrupted cellular circuitry that is involved in neuroblastoma
pathogenesis.
Quality assessment and biologic validation of the established
neuroblast expression profile demonstrated that the proper
cells were isolated and that their expression profiles are trust-
worthy. Next, we assessed the cell of origin hypothesis for
neuroblastomas. To this end, the transcriptional profile of the
neuroblasts was thoroughly compared with those of neurob-
lastoma tumors and normal tissues. These analyses con-
firmed that neuroblast and neuroblastoma cells indeed
present with highly similar expression profiles. These explor-
atory findings provide, for the first time, molecular support
for the cell of origin hypothesis. Also, they reinforce our
assumption that the neuroblast gene expression profile
constitutes a valid tool for further data mining of neuroblast-
oma gene expression patterns.
Following initial data validation and assessment of the cell of
origin hypothesis, we performed a series of data mining anal-
yses aimed at identifying genes and pathways that may be
involved in neuroblastoma oncogenesis and tumor biology. In
a first step, the neuroblastoma tumor expression profile was
compared with that of the neuroblasts, yielding 71 genes with
higher expression in neuroblasts and 565 genes with
increased expression in neuroblastoma. We subjected these
gene lists to a novel meta-analytical approach that allowed
comparison with 25 published neuroblastoma gene lists and
facilitated the detection of genes identified in at least one
other microarray study. Furthermore, we performed GO
analysis and we used a new approach to positional mapping
of the differentially expressed genes. In a second step,
following analysis of combined tumors, we sought genes dif-
ferentially expressed in carefully selected representative
cases of favorable and unfavorable neuroblastomas and
further analyzed the expression of these genes in neuroblasts.
This approach yielded 37 and 41 genes, respectively.
When combining the data from the above analyses, it was
apparent that many of the genes previously reported in the
context of neuroblastoma had been identified, thus under-
scoring the validity of our data mining approach. These
included MYCN, MYCN co-amplified genes such as DDX1,
known MYCN target genes such as ODC1 and MCM7, and
prognostic markers (MYCN, NTRK1, and CD44), as well as
various other genes such as ASCL1, ALK, BCL2, BIRC5, DLK1,
NME1, NME2 and NTRK3 that have previously been men-
tioned or studied within the context of neuroblastoma. For
some genes only circumstantial evidence for a role in neurob-
lastoma is present (WSB1, CDC42, PLAGL1, PRAME and
TGFBR3); that we identified these genes in the present study
warrants further investigations into their possible role in neu-
roblastoma development. Finally, several genes, for which no
evidence of involvement in neuroblastoma development has
yet been obtained, emerged for the first time from our analy-
ses. These include STAT3, IGSF4 and CACNA2D3, and they
should also be studied in further detail to determine their
possible role in neuroblastoma pathogenesis.
Although the present study is just a first step in a new strategy
of data mining of neuroblastoma gene expression profiles, we
nevertheless obtained new information that is particularly
interesting for the 17q region. Gain of distal 17q is not only the
most frequent chromosomal alteration in high stage
neuroblastoma but it is also the strongest independent
adverse prognostic genetic factor [21,22]. However, no func-
neuroblast > favorable NB
RNU2 17q -
neuroblast > favorable NB, neuroblast > unfavorable NB
LOC492304 11p -
Genes that are differentially expressed compared with neuroblasts among the differentially expressed genes in favorable neuroblastoma (NB) versus 
unfavorable neuroblastoma, with an indication of the number of neuroblastoma microarray studies in which these genes were found through NBGS 
analysis. NBGS, Neuroblastoma Gene Server.
Table 4 (Continued)
Genes that are differentially expressed in favorable vs. unfavorable neuroblastomaGenome Biology 2006, 7:R84
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ntional evidence has been provided for a specific role of 17q
genes in neuroblastoma development. A major obstacle is the
difficulty in refining the critical region for 17q gain that, as a
consequence, has remained very large, hampering selection
of functional candidates. Based on recent high-resolution
array-CGH (comparative genome hybridization) profiling of
17q breakpoints leading to gain for distal 17q, we have pro-
posed the hypothesis that the critical region for 17q gain is
located within a 5 Mb segment on 17q21.32-q22, immediately
distal to the most distal breakpoint (Vandesompele and cow-
orkers, unpublished data).
To substantiate this hypothesis, we performed positional
gene enrichment analysis on chromosome 17 for the genes
that are more highly expressed in neuroblastoma compared
to neuroblast. Interestingly, this yielded a highly significant
enrichment for two loci on the long arm of chromosome 17,
including the above mentioned region, further demonstrating
the high likelihood of the presence of a neuroblastoma dosage
sensitive gene. A total of 11 differentially expressed genes are
contained within this 17q21.3 segment, including NME1 and
NME2. The role of the latter two genes in cancer is controver-
sial, but once again these genes emerge from a neuroblastoma
study. Among the genes that are more highly expressed in
neuroblastoma, another interesting candidate was found to
be located just outside the enriched 17q21.3 segment but
within the same chromosome band, namely STAT3. This gene
encodes an oncogenic transcription factor that plays a central
role in the janus kinase (JAK)-signal transducer and activator
of transcription (STAT) signaling pathway, promoting growth
and survival of tumor cells, inducing tumor angiogenesis, and
suppressing antitumor immune responses. Of particular
interest is that STAT3 is also implicated in neurogenesis.
Given their documented role in cancer, STAT proteins have
been shown to be promising molecular targets for novel can-
cer therapies, including small molecule inhibitors of STAT
signaling. The finding of increased STAT3 expression might
also be of relevance in the light of the observed ALK over-
expression in this and previous studies [23,24], because
ALKis known to activate STAT3 by phosphorylation [25].
Suppression of activated ALK in neuroblastoma cells by RNA
interference was shown to lead to rapid apoptosis [26].
Positional mapping of the genes that are expressed to a lesser
degree in neuroblastomas than in neuroblasts yielded some
remarkable positional tumor suppressor candidate genes.
Among others, these include CASP9 and CDC42 (1p36),
which have already been studied in neuroblastoma [27,28];
CACNA2D3 (3p21-p22), which was recently proposed as a
tumor suppressor gene in lung cancer [29]; IGSF4 (11q23),
which is a known tumor suppressor gene in several cancers;
and DLK1 (14q). All of these genes have been mapped within
or near to previously defined shortest regions of overlap for
deletions in neuroblastoma and should therefore be consid-
ered for further functional studies.
Yet another interesting candidate neuroblastoma suppressor
gene is WSB1. This gene was found in four published neurob-
lastoma microarray studies to be more highly expressed in
favorable neuroblastomas. Moreover, WSB1 was very
recently shown to be associated with prognosis [30]. Recent
evidence indicated that WSB1 (WD repeat and SOCS box-
Table 5
Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study
Sample number Lab number % Tumor cells Stage MYCN amp Ploidy Adrenal 
localisation
Age Dead/alive Overall survival 
(months)
Type
NB1 01T15 80 4S No Tri Yes < 1 year Alive 61.4 Favorable
NB2 98T33 95 1 No Tri Yes < 1 year Alive 76.9 Favorable
NB3 96T82 90 1 No Tri Yes < 1 year Alive 115.5 Favorable
NB4 99T129 90 1 No Tri Yes < 1 year Alive 71.7 Favorable
NB5 01T28 90 4 Yes Di Yes > 1 year Dead 5.6 Unfavorable
NB6 03T304 100 3a No Di Abdominal > 1 year Alive 12.0 Unfavorable
NB7 03T236 90 4 No ND Yes > 5 year Dead 19.4 Unfavorable
NB8 00T54 70 1 No Tri Yes < 1 year Alive 62.6 Favorable
NB9 00T35 > 95 4 Yes Di Yes < 1 year Dead 13.7 Unfavorable
NB10 99T125 80 3 No Di Yes > 5 year Alive 79.3 Unfavorable
NB11 92W145 70 4 No ND ND > 5 year Dead 19.5 Unfavorable
NB12 02T192 100 4 Yes Di Abdominal > 5 year Dead 16.2 Unfavorable
NB13 D031 > 95 4 No Di Abdominal > 1 year Dead 64.8 Unfavorable
NB14 E002 > 80 4 No ND Abdominal > 1 year Alive 65.7 Unfavorable
NB15 E037 > 80 4 No ND Abdominal > 1 year Alive 45.3 Unfavorable
NB16 E044 > 80 4 No ND Yes < 1 year Alive 37.0 Unfavorable
NB17 E121 > 80 4 Yes ND Abdominal > 1 year Dead 78.4 Unfavorable
NB18 04T121 60 3 Yes Di Yes > 1 year Dead 6 Unfavorable
Based on stage, MYCN amplification, ploidy, and age at diagnosis, samples were subdivided into favorable or unfavorable type.
aNeuroblastoma or ganglioneuroblastoma. ND, not determined or unknown.Genome Biology 2006, 7:R84
R84.14 Genome Biology 2006,     Volume 7, Issue 9, Article R84       De Preter et al. http://genomebiology.com/2006/7/9/R84containing 1) is part of an E3 ubiquitin ligase and that it
exhibits similarity with an interchangeable F-box protein β-
TrCP1 that is implicated in nuclear factor-κB, Wnt/Wingless,
and hedgehog signaling pathways [31,32]. Together with
other unpublished data on the possible implications of the
Wnt pathway in neuroblastomas, we speculate that reduced
ubiquitination of β-catenin caused by low levels of WSB1
expression in unfavorable neuroblastomas could lead to
upregulation of several genes that are involved in cell prolif-
eration [33].
Finally, PLAGL1 was identified as a candidate neuroblastoma
tumor suppressor gene in the present study. This gene regu-
lates apoptosis and cell cycle arrest and plays a role in the con-
trol of cell fate during neurogenesis [34]. PLAGL1 is localized
on chromosome 6q24-q25, a region that is frequently deleted
or epigenetically modified in many solid tumors [35], includ-
ing neuroblastoma (unpublished data).
The dataset presented will also be of future value for the study
of sympathetic nervous system development and the develop-
mental stage from which neuroblastoma originates. Ideally,
more neuroblast samples from different gestation times
should be collected in order to gain broader insight. The
present neuroblast collections offer a glimpse into this devel-
opmental process, as illustrated by the expression of ASCL1
and DLK1. ASCL1 is a known early neurogenesis marker [36],
which was confirmed by the observed expression in the
immature self-renewing neural stem cells and the absence in
the more mature neuroblasts. The significantly higher
expression in part of the unfavorable neuroblastomas com-
pared with the neuroblasts might denote an earlier stage of
differentiation arrest or reflect a process of de-differentiation
of the unfavorable neuroblastoma cells. DLK1, on the other
hand, is expressed to a lesser degree in the unfavorable neu-
roblastoma than in the favorable tumors and the neuroblast
(in concordance with observations reported by Hsiao and
coworkers [37]). Later in neural development, DLK1 (delta-
like 1 homolog) downregulates ASCL1 (achaete-scute com-
plex-like 1) through NOTCH (notch homolog), further induc-
ing neuronal differentiation [38]. Hence, these expression
differences indicate a different time point of developmental
arrest for favorable and unfavorable neuroblastoma, as was
previously suggested.
Conclusion
The inclusion of normal neuroblasts in gene expression anal-
ysis of malignant neuroblastomas was shown to add signifi-
cant power to the identification of candidate neuroblastoma
genes. Inclusion of larger sets of neuroblastoma tumors with
well characterized genomic alterations and positional map-
ping of the genes in critically involved genomic regions in
neuroblastomas will be crucial for tracing back the molecular
basis of neuroblastoma.
Materials and methods
Fetal and tumor material
Ethical approval was obtained for the collection of fetal adre-
nal glands from fetuses aborted for clinical reasons (Ethics
committee Erasme Hospital, Brussels, Belgium; approval no.:
OM021). The induced abortion was performed by prostaglan-
din instillation to the patient. The adrenals were removed
during necropsy and snap-frozen in liquid nitrogen within 3
hours after delivery. Neuroblastoma tumors were collected in
the Center for Medical Genetics (Ghent, Belgium; n = 12), in
the National Center for Medical Genetics (Dublin, Ireland; n
= 1), and in the University Children's Hospital of Essen
(Essen, Germany; n = 5). For this study, we preferentially
selected tumors that were localized in the adrenal gland (11/
18). Based on INSS stage (international neuroblastoma stag-
ing system), MYCN status, ploidy and age at diagnosis, and
for some cases pathologic rapports, samples were divided into
favorable or unfavorable neuroblastoma (Table 5).
Hematoxylin and eosin staining, 
immunohistochemistry, and laser capture 
microdissection
Fetal adrenal glands were embedded in Tissue-Tek OCT com-
pound (Sakura, Torrance, CA, USA). Immunohistochemical
staining was performed as described previously [8]. For
microdissection, cryosections were first stained with hema-
toxylin and eosin, and mounted in order to scan for neurob-
last clusters. When neuroblast clusters were found, stained
but unmounted cryosections were prepared for laser capture
microdissection. Embedding, sectioning, staining, and laser
capture microdissection of neuroblast clusters and surround-
ing cortex cells was performed as described previously [9].
RNA isolation and quality assessment
Microdissected cells were collected in RNA extraction buffer,
followed by RNA extraction and DNase treatment on column
(Qiagen, Venlo, Netherlands). RNA of the tumor samples was
extracted using the RNeasy Mini kit (Qiagen), in accordance
with the manufacturer's instructions. Four of the neuroblast-
oma tumor pieces were first mixed with Lysing Matrix D
microbeads (Qbiogene, Illkirch, France) and 700 µl RTL
buffer (Qiagen), and homogenized using FastPrep FP220
(Qbiogene). A fraction of the RNA was used for cDNA synthe-
sis after DNase treatment (described by Vandesompele and
coworkers [39]). RNA quality was measured with the RNA
Nano or Pico LabChip kit (Agilent, Diegem, Belgium) using 1
µl of the RNA isolates.
Oligonucleotide chip analysis and data mining
For each of the three fetal adrenal glands, the different neu-
roblast RNA isolates were pooled, amplified using a two-
round labeling protocol, and hybridized to HG-U133A oligo-
nucleotide chips (Affymetrix, Santa Clara, CA, USA), contain-
ing 18,400 transcripts including 14,500 well characterized
human genes (protocol described previously [40]). The same
amplification protocol was applied to RNA of three cortexGenome Biology 2006, 7:R84
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nsamples and approximately 100 ng RNA of 18 neuroblastoma
tumors. The homogeneity of the subgroups (neuroblast, cor-
tex, favorable and unfavorable neuroblastoma) allowed us to
use a limited number of samples for expression profiling. Sev-
eral technical parameters demonstrate that the hybridization
was of good quality (Additional data file 1(d)).
We obtained the raw data from the Genomics Institute of the
Novartis Foundation compendium of normal tissues consist-
ing of 79 normal tissues assayed in duplicate using the
Affymetrix HG-U133A array [12]. Raw HG-U133A Affymetrix
array data from three neural stem cells were kindly provided
by Wright and coworkers [13].
CEL files were loaded in the R-Bioconductor (BioC) software
and normalized with the Robust Multi Chip Average (RMA)
method [41]. Identification of differentially expressed genes
for pairwise comparisons were performed using the Rank-
Prod R-package, which is based on the Rank Product princi-
ple [10]. We used the GoHyperG function from the BioC
project to find over-represented biologic process GO
categories from the gene lists using hypergeometric test for
significance. KEGG pathway analysis was performed with the
Webgestalt web interface using hypergeometric test for sig-
nificance [42].
Meta-analyses of published neuroblastoma microarray data
were performed with the NBGS (see Additional data fiile 3 for
detailed information).
Positional gene enrichment analysis was performed with in-
house developed R-Bioconductor script PGE (De Preter and
coworkers, unpublished data) [15]. PGE scans the entire
genome using a moving window with a user-defined width (5
Mb) and step size (1 Mb). In each window, the -10log(p) of the
Fisher Exact Test is calculated. This test was used to investi-
gate whether there is an association between the gene list and
a particular chromosomal region (the window under investi-
gation). As such, it will identify regions that contain more (or
less) genes in the gene list than expected by chance. The
(known) unequal distribution of the genes along the chromo-
somes is taken into account, because the number of genes
from the list that are located in the region is compared with
the total number of genes in that particular region. Correction
for multiple testing is performed using the false discovery rate
method of Benjamini and Hochberg [43], using the R-mult-
test package.
Expression microarray data were submitted to ArrayExpress
[44], accession number E-MEXP-669.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 includes docu-
ments on RNA quality and quantity measures, validation of
Affymetrix chip results, and Affymetrix chip quality parame-
ters [39,45-49]. Additional data file 2 lists genes that are dif-
ferentially expressed in neuroblast versus cortex samples, in
neuroblast versus favorable (F) and/or unfavorable (UF) neu-
roblastoma, and in favorable versus unfavorable neuroblast-
oma (identified using Rank Product algorithm). Additional
data file 3 provides results of NBGS analysis of the genes that
are differentially expressed between neuroblasts and (favora-
ble and/or unfavorable) neuroblastomas (gene lists in Addi-
tional data file 1). Additional data file 4 lists the genes of GO
class neurogenesis and proneural genes that are expressed in
neuroblast samples (> 36th percentile) [50-54].
Additional data file 1RNA quality and quantity measures, validation of Affymetrix chip resul s, nd Affym trix chip quality parametersClick here for file 2Genes th t a e iff rentially xpres ed in neu oblast versus cortex samples, in n urobl st versus f vorable (F) and/or unfavo able (UF) n urobl stoma, and n f vo able versus unfavorabl  n urobl s oma 3sults of NBGS an lys s of the g nes that are ifferentially exp e ed betwe n n urob asts nd (f o abl  a d/ r unfavorable)s (gene li ts in Additional da a file 1)4of GO class euroge si  and pr e al g nes that are in neuroblas  a pl s (> 36 p rce til )
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